RxDoctor Payments Data

Kerry Hendershot, MD

Family Medicine · Lubbock, TXNPI 1700849544

Payments from drug & device makers

$5,939in general payments, 2019–2025

Across 391 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$926
  • Novo Nordisk$608
  • Lilly USA, LLC$492
  • Pfizer$408
  • Supernus Pharmaceuticals, Inc.$366
  • GSK$291
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$5,81498%
  • Education$1262%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,939 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$283,615
Medicare patients
715
Services billed
7,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide147$171,187
JardianceEmpagliflozin117$146,396
EliquisApixaban114$108,049
OzempicSemaglutide58$62,090
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$46,682
JanuviaSitagliptin Phosphate35$45,069
TrulicityDulaglutide42$42,661
ProliaDenosumab23$38,794
Tresiba Flextouch U-200Insulin Degludec33$37,450
MyrbetriqMirabegron34$26,574
XareltoRivaroxaban24$25,494
Humalog Kwikpen U-200Insulin Lispro32$23,617
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen532$22,814
Tresiba Flextouch U-100Insulin Degludec36$21,691
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog34$21,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$492$213,848189 claims
Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat$27$161,088142 claims
PfizerEliquis, Premarin$408$120,528139 claims
Novo NordiskOzempic, Levemir$608$70,39674 claims
GSKTrelegy Ellipta, Incruse Ellipta$291$54,27077 claims
MerckJanuvia$120$45,06935 claims
AmgenProlia$130$38,79423 claims
Astellas Pharma US IncMyrbetriq$176$26,57434 claims
Johnson & JohnsonXarelto$41$25,49424 claims
AstraZenecaFarxiga$102$17,93615 claims
BayerKerendia$149$17,20416 claims
AbbVieLinzess$926$11,52715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →